



GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (INDIA)
CIN.: L26109GA1981PLC000469

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website : www.gkb.net

May 30, 2025

Department of Corporate Services
BSE Limited
Phiroze Jeejubhoy Towers, Dalal Street
Mumbai - 400 001

Dear Sir,

Ref: Scrip Code No. : 533212

Sub: Outcome of Board Meeting of GKB Ophthalmics Limited held on May 30, 2025.

The meeting of the Board of Directors of the Company was held on May 30, 2025, which approved and took on record the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025.

Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find the following:

1. Standalone Financial Results for the quarter and year ended March 31, 2025, together with Auditors' Report.
2. Consolidated Financial Results for the quarter and year ended March 31, 2025, together with Auditors' Report.
3. A declaration from CFO with respect to Audit Report with unmodified opinion for the financial year ended March 31, 2025, in terms of SEBI Circular no. CIR/ CFD/CMD/56/2016 dated May 27, 2016.

The above Audited Financial Results and Auditors' Reports' are available on the Company's website www.gkb.net and on the BSE website www.bseindia.com

The Board of Directors has decided:-

4. To pass over the dividend for the year 2024-25.
5. To hold the Annual General Meeting of the Company on Thursday, August 21, 2025 at 11:00 A.M., through Video Conferencing ("VC") or Other Audio Visual Means ("OAVM") in accordance with the relevant Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.
6. To close the Share Transfer Books and the Register of Members of the Company from Friday, August 15, 2025 to Thursday, August 21, 2025(both days inclusive).
7. To re-appoint RRK & Co, Chartered Accountants as Internal Auditors of the Company for the Financial Year 2025-26.





GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (INDIA)
CIN.: L26109GA1981PLC000469

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website : www.gkb.net

: 2 :

8. To recommend the appointment of CS Girija G. Nagvekar, Practising Company Secretary (FCS: 10358 , COP: 10335, Peer Review: 2001/2022) as the Secretarial Auditor of the Company for a period of five consecutive financial years, commencing from FY 2025-26 subject to approval of Shareholders of the Company in the ensuing Annual general Meeting of the Company .

The detailed disclosures as required under Regulation 30 of SEBI (LODR) Regulations, 2015, and the SEBI Circular no. circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13.07.2023 is enclosed as Annexure "A":

The Board of Directors' Meeting started at 5: 15 P.M. and ended at 6:06 P.M., on the same day.

Kindly take the information on record.

Thanking you,

Yours faithfully,
For GKB Ophthalmics Ltd.,

Pooja Bicholkar
Company Secretary





GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (INDIA)
CIN.: L26109GA1981PLC000469

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website : www.gkb.net

: 3 :

Annexure "A"

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015, and the SEBI Circular dated 13.07.2023 are as under:

Re-appointment of RRK & Co., Chartered Accountants as the Internal Auditors of the Company

Sr. No.	Details of event(s) that need to be provided	Information of such event(s)
1.	Name	RRK & Co., Chartered Accountants
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment
3.	Date of appointment/Re-appointment/cessation (as applicable)	Date of re-appointment: 30 th May, 2025 Term of appointment : Financial Year 2025-26.
4	Brief Profile (In case of appointment/Re-appointment)	Rohit Kalbhairav and Vishal Sutar, Partners of RRK & Co., are fellow members of Institute of Chartered Accountants of India. CA Rohit Kalbhairav is having expertise in the areas of external and internal audits of listed and unlisted Companies. CA Vishal Sutar has expertise in the area of Bank Audit.
5	Disclosure of relationship between directors (In case of appointment)	Not Applicable

Appointment of CS Girija G. Nagvekar, Practising Company Secretary (FCS: 10358 , COP: 10335, Peer Review: 2001/2022) as the Secretarial Auditor of the Company

Sr. No.	Details of event(s) that need to be provided	Information of such event(s)
1.	Name	CS Girija G. Nagvekar, Practising Company Secretary (Secretarial Auditor)
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/Re-appointment/cessation (as applicable) & terms of appointment	Date of appointment: 30 th May, 2025 Term of appointment : Five consecutive financial years commencing from FY 2025-26
4	Brief Profile (In case of appointment/Re-appointment)	CS Girija G. Nagvekar, Practising Company Secretary has extensive experience of over 13 years in the field of Corporate Secretarial, Securities Laws and FEMA.
5	Disclosure of relationship between directors (In case of appointment)	Not Applicable



**GKB Ophthalmics Limited**

CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526

Tel No. (0832) 2257253 / 6714444, Fax No. (0832) 2257044 E-mail: gkbophthalmics@gkb.net

Website: www.gkb.net

Statement of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2025

(Rs. In Lakhs except earnings per share data)

	Particulars	Quarter ended			Year Ended	
		Mar 31, 2025	Dec 31, 2024	Mar 31, 2024	Mar 31, 2025	Mar 31, 2024
		(Refer Note 6)	(Unaudited)	(Refer Note 6)	(Audited)	(Audited)
	Income:					
1	Revenue from operations	842.63	744.67	735.66	3,274.94	3,118.05
2	Other income	1.10	181.43	19.51	197.22	207.74
3	Total Income (1+2)	843.73	926.10	755.17	3,472.16	3,325.79
	Expenses:					
4	a) Cost of materials consumed	481.28	417.01	335.33	1,889.59	1,639.74
	b) Purchases of stock -in-trade	0.17	0.41	2.94	6.53	6.39
		21.76	(14.21)	44.19	(49.82)	25.54
	c) Changes in inventories of finished goods and work-in-progress					
	d) Employee benefits expense	272.72	267.64	265.90	1,088.35	921.67
	e) Finance costs	59.73	48.14	48.22	188.67	159.33
	f) Depreciation and amortisation expense	66.44	66.73	64.03	264.31	258.60
	g) Other expenses	185.43	156.12	128.03	688.16	652.14
	Total expenses	1,087.53	941.84	888.64	4,075.79	3,663.41
5	Profit / (Loss) before tax (3-4)	(243.80)	(15.74)	(133.47)	(603.63)	(337.62)
6	Tax expenses					
	a) Current Tax	-	-	-	-	-
	b) Deferred Tax	4.15	1.00	3.86	7.16	4.02
7	Profit / (Loss) for the periods / years (5-6)	(247.95)	(16.74)	(137.33)	(610.79)	(341.64)
8	Other comprehensive income:					
	Items that will not be reclassified to profit or loss					
	Remeasurement of net defined benefit liability - gain / (loss)	(15.94)	(3.86)	(14.83)	(27.52)	(15.45)
	Income tax effect	4.15	1.00	3.86	7.16	4.02
	Other comprehensive Income / (loss) for the periods / years	(11.79)	(2.86)	(10.97)	(20.36)	(11.43)
9	Total Comprehensive income / (loss) for the periods / years (7+8)	(259.74)	(19.60)	(148.30)	(631.15)	(353.07)
10	Paid-up equity share capital (face value of share - Rs. 10 each fully paid up)	504.06	504.06	504.06	504.06	504.06
11	Reserves excluding revaluation reserve				1,263.36	1,894.51
12	Earnings Per Share (face value of Rs. 10 each)					
	(a) Basic (in Rs.)	(4.92)	(0.33)	(2.73)	(12.12)	(6.78)
	(b) Diluted (in Rs.)	(4.92)	(0.33)	(2.73)	(12.12)	(6.78)
	* Not Annualised	*	*	*		

See accompanying notes



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Notes:

1 Standalone Statement of Assets and Liabilities

(Rs. in Lakhs)

Particulars	As at Mar 31, 2025 (Audited)	As at Mar 31, 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,444.20	1,589.29
Capital work-in-progress	378.30	378.30
Other intangible assets	-	0.10
Financial assets		
(i) Investments	1,189.55	1,189.55
(ii) Other Financial assets	4.90	0.73
Non current tax assets (net)	28.75	25.88
Other non-current assets	235.12	230.09
Total Non-current assets	3,280.82	3,413.94
Current Assets		
Inventories	608.17	468.82
Financial Assets		
(i) Investments	0.08	0.08
(ii) Trade Receivables	748.99	686.13
(iii) Cash and cash equivalent	0.04	7.26
(iv) Bank balances other than Cash and cash equivalent	88.54	62.84
(vi) Other financial assets	184.07	156.07
Other current assets	37.88	44.35
Total current assets	1,667.77	1,425.55
TOTAL ASSETS	4,948.59	4,839.49
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	504.06	504.06
Other equity	1,263.36	1,894.51
Total Equity	1,767.42	2,398.57
LIABILITIES		
Non - Current liabilities		
Financial liabilities		
(i) Borrowings	725.15	64.38
(ii) Other financial liabilities	-	94.88
Provisions	248.40	198.77
Total Non- Current liabilities	973.55	358.03
Current liabilities		
Financial liabilities		
(i) Borrowings	1,083.46	1,043.55
(ii) Trade Payables		
Total outstanding dues of micro enterprises and small enterprises	122.73	95.06
Total outstanding dues of creditors other than micro enterprises and small enterprises	574.84	628.03
(iii) Other financial liabilities	285.13	162.17
Other current liabilities	53.21	68.84
Provisions	88.25	85.24
Total Current liabilities	2,207.62	2,082.89
TOTAL EQUITY AND LIABILITIES	4,948.59	4,839.49



2 Standalone Statement of Cash Flows

(Rs. in Lakhs)

	Particulars	Year ended	
		Mar 31, 2025 (Audited)	Mar 31, 2024 (Audited)
A	Cash flow from operating activities		
	(Loss) before tax	(603.63)	(337.62)
	Adjustments for:		
	Depreciation and amortization expenses	264.31	258.60
	Notional lease rental income	-	(5.39)
	Finance costs	188.67	159.33
	Provision for / (Reversal of) Doubtful / Bad Debts (net)	10.28	(1.75)
	Unrealised exchange loss / (gain) (net)	1.68	3.31
	Dividend income	(176.92)	(167.04)
	Interest income	(4.12)	(3.80)
	Liabilities written back	(1.25)	(15.74)
	(Gain)/ loss on sale of property, plant and equipment (net)	(3.98)	(4.48)
	Operating Profit/ (Loss) before working capital changes	(324.96)	(114.58)
	Changes in working capital		
	Decrease/ (Increase) in inventories	(139.35)	137.21
	Decrease/ (Increase) in trade receivables	(73.03)	(196.36)
	Decrease/ (Increase) in financial assets	-	4.89
	Decrease/ (Increase) in Non current assets	4.97	9.83
	Decrease/ (Increase) in current assets	6.47	(8.33)
	(Decrease)/ Increase in trade payables	(26.04)	215.37
	(Decrease)/ Increase in financial liabilities	41.65	22.69
	(Decrease)/ Increase in provisions	25.12	34.65
	(Decrease)/ increase in other current liabilities	(15.64)	31.84
	Cash generated from / (Used in) operations	(500.81)	137.21
	Income tax (paid) / refund (net)	(2.87)	(0.88)
	Net cash flows from / (Used in) operating activities (A)	(503.68)	136.33
B	Cash flow from Investing activities		
	Payment for purchase of property, plant and equipment and intangible assets	(142.70)	(125.03)
	Proceeds from sale / disposal of property, plant and equipment	3.98	5.00
	Net proceeds from / (amount deposited into) fixed deposits	(29.87)	(28.82)
	Interest received	1.10	1.02
	Dividend received	151.94	185.26
	Net cash flow from / (Used in) investing activities (B)	(15.55)	37.43
C	Cash flow from Financing activities		
	Proceeds from / (Repayments of) short term borrowings (net)	(50.86)	34.17
	Proceeds from long term borrowings	800.00	-
	Repayment of long term borrowings	(48.46)	(47.84)
	Interest paid	(188.67)	(160.12)
	Net cash flow from / (Used in) financing activities (C)	512.01	(173.79)
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	(7.22)	(0.03)
	Cash and cash equivalents at the beginning of the year	7.26	7.29
	Cash and cash equivalents at the end of the year	0.04	7.26
	Cash and cash equivalents comprise		
	Balances with banks		
	On current accounts	0.03	7.24
	Cash on hand	0.01	0.02
	Total Cash and cash equivalent at end of the year	0.04	7.26

GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

3 The above standalone financial results for quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 30, 2025. The Standalone annual financial results have been subject to audit by the Statutory Auditors of the Company.

4 The utilisation / status of funds raised from preferential issue is as follows :-

Particulars	As at March 31, 2025 (Rs. In lakhs)	As at March 31, 2024 (Rs. In lakhs)
Towards funding growth plans - organic and inorganic	1,170.00	1,170.00
Towards scaling up of operations, long term capital requirements and other general corporate purpose	335.05	335.05
Total funds utilised (A)	1,505.05	1,505.05
Unutilised amount lying in Escrow account (B)	-	7.22
Total funds raised (A + B)	1,505.05	1,512.27

5 The Company operates in one primary segment only, i.e. Ophthalmics Lenses and therefore Ind AS 108 - Operating Segment is not applicable.

6 The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial years, which were subject to limited review by the statutory auditors.

7 The figures of the previous year / periods have been reclassified / regrouped wherever necessary to conform to current period.

**For and on behalf of the Board of Directors
of GKB Ophthalmics Limited**

KRISHNA
GOPAL
GUPTA

Digitally signed by
KRISHNA GOPAL GUPTA
Date: 2025.05.30
18:06:05 +05'30'

K. G. Gupta
Managing Director
DIN : 00051863

Place : Mapusa - Goa
Date : May 30, 2025

Independent Auditor's Report on Standalone Audited Annual Financial Results of GKB Ophthalmics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of GKB Ophthalmics Limited

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying statement of standalone annual financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Company') for the year ended March 31, 2025 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net loss, and other comprehensive income and other financial information of the Company for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true

MSKA & Associates

Chartered Accountants

and fair view of the net loss, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended, issued thereunder and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

Auditors' Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

MSKA & Associates

Chartered Accountants

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters:

1. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

NITIN
MANOHAR
JUMANI

Digitally signed by
NITIN MANOHAR
JUMANI
Date: 2025.05.30
18:39:01 +05'30'

Nitin Manohar Juman
Partner
Membership No: 111700
UDIN: 25111700BMKSHF5984

Place: Pune
Date: May 30, 2025



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526
Tel No. (0832) 2257253 / 6714444, Fax No. (0832) 2257044 E-mail: gkbophthalmics@gkb.net

Website: www.gkb.net

Statement of Audited Consolidated Financial Results for the Quarter and Year ended March 31, 2025

(Rs. in Lakhs except earnings per share data)

	Particulars	Quarter Ended			Year Ended	
		Mar 31, 2025 (Refer Note 7)	Dec 31, 2024 (Unaudited)	Mar 31, 2024 (Refer Note 7)	March 31, 2025 (Audited)	March 31, 2024 (Audited)
	Income:					
1	Revenue from operations	3,102.29	2,580.41	2,155.76	10,898.76	8,825.40
2	Other income	33.62	48.47	49.78	133.10	150.56
3	Total Income (1+2)	3,135.91	2,628.88	2,205.54	11,031.86	8,975.96
4	Expenses:					
	a) Cost of materials consumed	646.17	433.48	338.40	2,115.32	1,504.53
	b) Purchases of stock in trade	1,868.01	1,507.07	1,263.66	6,175.65	4,708.85
			(302.91)	(160.03)	(946.37)	(239.60)
	c) Changes in inventories of finished goods, stock in trade and work-in-progress	(263.11)				
	d) Employee benefits expense	453.84	429.45	376.71	1,725.74	1,375.83
	e) Finance costs	63.04	63.48	57.36	237.08	190.33
	f) Depreciation and amortisation expense	79.92	76.67	71.68	308.70	289.87
	g) Other expenses	682.69	604.50	336.44	2,106.67	1,417.88
	Total expenses	3,530.56	2,811.74	2,284.22	11,722.79	9,247.69
5	Profit / (Loss) before Share in profit / (loss) of an associate & tax (3-4)	(394.65)	(182.86)	(78.68)	(690.93)	(271.73)
6	Share in profit / (loss) of an associate	1.20	(2.99)	9.74	18.31	(5.86)
7	Profit/(loss) before tax (5+6)	(393.45)	(185.85)	(68.94)	(672.62)	(277.59)
8	Tax expenses					
	a) Current Tax	14.84	4.72	18.81	28.74	18.81
	b) Prior Period Tax	0.44	(1.04)	(2.21)	(0.60)	(2.21)
	c) Deferred Tax	4.15	1.00	3.86	7.16	4.02
9	Profit / (loss) for the periods / year (7-8)	(412.88)	(190.53)	(89.40)	(707.92)	(298.21)
10	Other comprehensive Income :-					
	Items that will not be reclassified to profit or loss					
	Remeasurement of net defined benefit liability	(15.94)	(3.86)	(14.83)	(27.52)	(15.45)
	Income tax effect	4.15	1.00	3.86	7.16	4.02
	Other comprehensive Income / (loss) for the period / year	(11.79)	(2.86)	(10.97)	(20.36)	(11.43)
11	Total Comprehensive Income / (loss) for the period / year (9+10)	(424.67)	(193.39)	(100.37)	(728.28)	(309.64)
12	Profit/(Loss) for the period / year attributable to					
	Equity holders of the parent	(354.59)	(203.00)	(91.41)	(704.48)	(281.05)
	Non-controlling interest	(58.29)	12.47	2.01	(3.44)	(17.16)
	Total	(412.88)	(190.53)	(89.40)	(707.92)	(298.21)
	Other comprehensive income / (loss) for the period / year attributable to					
	Equity holders of the parent	(11.79)	(2.86)	(10.97)	(20.36)	(11.43)
	Non-controlling interest	-	-	-	-	-
	Total	(11.79)	(2.86)	(10.97)	(20.36)	(11.43)
	Total Comprehensive income / (loss) for the period / year attributable to					
	Equity holders of the parent	(366.38)	(205.86)	(102.38)	(724.84)	(292.48)
	Non-controlling interest	(58.29)	12.47	2.01	(3.44)	(17.16)
	Total	(424.67)	(193.39)	(100.37)	(728.28)	(309.64)
13	Paid-up equity share capital (face value of share - Rs. 10 each)	504.06	504.06	504.06	504.06	504.06
14	Reserves excluding revaluation reserve				4,699.83	5,473.06
15	Earnings Per Share (face value of Rs. 10 each)					
	(a) Basic (in Rs.)	(7.03)	(4.03)	(1.81)	(13.98)	(5.58)
	(b) Diluted (in Rs.)	(7.03)	(4.03)	(1.81)	(13.98)	(5.58)
	* Not Annualised	*	*	*		

See accompanying notes



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

Notes:

1 Statement of Consolidated Assets and Liabilities

(Rs. in Lakhs)

Particulars	As at Mar 31, 2025 (Audited)	As at Mar 31, 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,703.07	1,821.42
Capital work-in-progress	390.59	390.59
Other intangible assets	-	0.10
Financial assets		
(i) Investments	201.22	182.91
(ii) Other Financial assets	4.90	0.73
Non-current Tax Assets (Net)	10.99	25.58
Other non-current assets	271.70	280.95
Total Non-current assets	2,582.47	2,702.28
Current Assets		
Inventories	5,037.78	4,001.88
Financial Assets		
(i) Investments	0.08	0.08
(ii) Trade Receivables	2,549.15	2,839.94
(iii) Cash and cash equivalents	302.12	323.24
(iv) Bank balances other than cash and cash equivalents	1,080.05	1,460.41
(v) Other financial assets	49.15	15.83
Other current assets	920.67	106.35
Total current assets	9,939.00	8,747.73
TOTAL ASSETS	12,521.47	11,450.01
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	504.06	504.06
Other equity	4,699.83	5,473.06
Non - Controlling Interest	439.76	443.20
Total Equity	5,643.65	6,420.32
LIABILITIES		
Non - Current liabilities		
Financial liabilities		
(i) Borrowings	308.16	105.16
Provisions	331.04	301.83
Total Non- Current liabilities	639.20	406.99
Current liabilities		
Financial liabilities		
(i) Borrowings	1,141.46	1,043.55
(ii) Trade Payables		
Total outstanding dues of micro enterprises and small enterprises	122.73	95.06
Total outstanding dues of creditors other than micro enterprises and small enterprises	3,805.82	3,214.30
(iii) Other financial liabilities	212.85	160.05
Other current liabilities	867.51	56.48
Provisions	88.25	53.26
Total Current liabilities	6,238.62	4,622.70
TOTAL EQUITY AND LIABILITIES	12,521.47	11,450.01



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

2 Statement of Consolidated Cash Flows

(Rs. in Lakhs)

	Particulars	Year Ended	Year Ended
		Mar 31, 2025 (Audited)	Mar 31, 2024 (Audited)
A	Cash flow from operating activities		
	Profit / (Loss) before tax	(672.62)	(277.59)
	Adjustments for:		
	Depreciation and amortization expense	308.70	289.87
	Finance cost	237.08	190.33
	Provision for / (Reversal of) Doubtful / Bad Debts (net)	522.74	15.22
	Liabilities written back	(1.25)	(15.86)
	Unrealised exchange loss / (gain) (net)	(1.67)	(1.69)
	(Gain)/ loss on sale of property, plant and equipment (net)	(3.98)	(4.48)
	Share of Profit in Associate	(18.31)	5.86
	Dividend income	(0.04)	(0.04)
	Interest income	(107.43)	(88.89)
	Operating Profit / (Loss) before working capital changes	263.22	112.73
	Changes in working capital		
	Decrease/ (Increase) in inventories	(1,035.90)	(127.93)
	Decrease/ (Increase) in trade receivables	(258.21)	(82.60)
	Decrease/ (Increase) in financial assets	(15.37)	52.55
	Decrease/ (Increase) in Non current assets	19.27	(38.10)
	Decrease/ (Increase) in current assets	(814.32)	(7.30)
	(Decrease)/ Increase in trade payables	597.63	946.79
	(Decrease)/ Increase in financial liabilities	66.55	(3.87)
	(Decrease)/ increase in other current liabilities	811.03	(455.75)
	(Decrease)/ Increase in provisions	36.68	44.13
	Cash generated from / (Used in) operations	(329.42)	440.65
	Income tax (paid) / refund (net)	(13.55)	(18.60)
	Net cash flows from / (Used in) operating activities (A)	(342.97)	422.05
B	Cash flow from Investing activities		
	Payment for purchase of property, plant and equipment and intangible assets	(214.72)	(207.61)
	Proceeds from sale / disposal of property, plant and equipment	3.98	5.00
	Refund of capital advance	-	95.00
	Net proceeds from / (amount deposited into) fixed deposits	376.19	(251.39)
	Interest received	89.48	187.71
	Dividend received	0.04	0.04
	Net cash flow from / (Used in) investing activities (B)	254.97	(171.25)
C	Cash flow from Financing activities		
	Proceeds from / (Repayment of) short term borrowings (net)	(50.86)	34.17
	Repayment of long term borrowings	(89.24)	(51.22)
	Proceeds from long term borrowings	441.01	44.20
	Interest paid	(234.03)	(191.12)
	Net cash flow from / (Used in) financing activities (C)	66.88	(163.97)
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	(21.12)	86.83
	Cash and cash equivalents at the beginning of the period	323.24	236.41
	Cash and cash equivalents at the end of the Period	302.12	323.24
	Cash and cash equivalents comprise		
	Balances with banks		
	On current accounts	296.20	317.56
	Cash on hand	5.92	5.68
	Total cash and bank balances at end of the period	302.12	323.24



GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

3 The consolidated financial results include results of the following companies:

Name of the Company	Relationship
1. GKB Ophthalmics Limited	Holding Company
2. GSV Ophthalmics Private Limited	Subsidiary
3. GKB Ophthalmics Products [FZE]	Wholly Owned Subsidiary
(including its following Subsidiaries and Associate)	
a. Lensco - The lens company (Subsidiary)	
b. Prescription Optical Products LLC (Subsidiary)	
c. PRIME OPHTHALMIC PRODUCTS (PTY) LTD (Subsidiary)	
d. GKB Vision FZC (Associate - 49% Holding)	

4 The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective meetings held on May 30, 2025. The consolidated annual financial results have been subject to audit by the Statutory Auditors of the Holding Company.

5 The utilisation / status of funds raised from preferential issue is as follows :-

Particulars	As at March 31, 2025 (Rs. In lakhs)	As at March 31, 2024 (Rs. In lakhs)
Towards funding growth plans - organic and inorganic	1,170.00	1,170.00
Towards scaling up of operations, long term capital requirements and other general corporate purpose	335.05	335.05
Total funds utilised (A)	1,505.05	1,505.05
Unutilised amount lying in Escrow account (B)	-	7.22
Total funds raised (A + B)	1,512.27	1,512.27

6 The Group operates in one primary segment only, i.e. Ophthalmics Lenses and therefore Ind AS 108 - Operating Segment is not applicable.

7 The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial years, which were subject to limited review by the statutory auditors.

8 The figures of the previous year / periods have been reclassified / regrouped wherever necessary to confirm to current year.

For and on behalf of the Board of Directors
of GKB Ophthalmics Limited

KRISHNA
GOPAL
GUPTA

Digitally signed by
KRISHNA GOPAL GUPTA
Date: 2025.05.30
18:07:07 +05'30'

K. G. Gupta
Managing Director
DIN : 00051863

Place : Mapusa - Goa
Date : May 30, 2025

Independent Auditor's Report on Consolidated Audited Annual Financial Results of the GKB Ophthalmics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of GKB Ophthalmics Limited

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated annual financial results of GKB Ophthalmics Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), and its associate for the year ended March 31, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial information of the subsidiaries, the aforesaid Statement:

(i) includes the annual financial results of Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	GSV Ophthalmics Private Limited	Subsidiary
2	GKB Ophthalmics Products [FZE]	Wholly owned subsidiary
	(including its following Subsidiaries and Associate)	
	a. Lensco -The Lens Company (Subsidiary)	
	b. Prescription Optical Products LLC (Subsidiary)	
	c. Prime Ophthalmic Products (PTY) Ltd (Subsidiary)	
	d. GKB Vision FZC (Associate) - 49% Holding	

(ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net loss, and other comprehensive loss and other financial information of the Group and its associate for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, and of its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditor(s) in terms of their reports referred to in "Other Matter(s)" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net loss, and other comprehensive loss and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and of its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the Group and of its associate to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group and of its associates or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for overseeing the financial reporting process of the Group and of its associate.

Auditors' Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

MSKA & Associates

Chartered Accountants

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and of its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and of its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group and of its associate to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters:

1. The Statement includes the audited financial information of two subsidiaries and one step-down subsidiary whose financial information reflect total assets of Rs. 10,140.51 lakhs as at March 31, 2025, total revenue of Rs. 8,297.28 lakhs, net profit after tax of Rs. 27.73 lakhs, total comprehensive income of Rs. 27.73 lakhs, for the period from April 01, 2024 to March 31, 2025 and net cash outflow of Rs. 27.38 lakhs for the year ended as on date respectively, as considered in the Statement, which have been audited by the other auditors whose reports on financial information of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of

MSKA & Associates

Chartered Accountants

these Subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

Our Opinion is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

2. The Statement includes the unaudited financial information of two step down subsidiaries whose financial information reflect total assets of Rs. 98.53 lakhs as at March 31, 2025, total revenue of Rs. 483.85 lakhs, net loss after tax of Rs. 4.17 lakhs, and total comprehensive loss of Rs. 4.17 lakhs, for the period from April 01, 2024 to March 31, 2025 and net cash inflow of Rs. 13.48 lakhs for the year ended as on date, as considered in the Statement. The Statement also includes unaudited financial information of associate, whose financial information reflects Group share of net profit after tax of Rs.18.31 lakhs and Groups share of total comprehensive income of Rs.18.31 lakhs for the year ended March 31,2025, as considered in the Statement. These unaudited financial information have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial information are not material to the Group.

Our Opinion is not modified with respect to the financial information certified by the Management.

3. The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

NITIN
MANOHAR
JUMANI

Digitally signed by
NITIN MANOHAR
JUMANI
Date: 2025.05.30
18:36:38 +05'30'

Nitin Manohar Juman
Partner
Membership No.: 111700
UDIN: 25111700BMKSHI7648

Place: Pune
Date: May 30, 2025



GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (INDIA)
CIN.: L26109GA1981PLC000469

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website : www.gkb.net

May 30, 2025

Department of Corporate Services
BSE Limited
Phiroze Jeejubhoy Towers, Dalal Street
Mumbai - 400 001

Dear Sir,

Ref : Scrip Code No. : 533212

Sub: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


DECLARATION

Pursuant to second proviso of Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that, the Statutory Auditors of the Company, M/s. MSKA & Associates, Chartered Accountants, Floor 7, Wing A, Sunteck Kanaka Corporate Park, Opp. Shram Bhakti Bhavan, Patto Panaji, Patto Centre- Panjim, Goa. 403001 (FRN 105047W), have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company (Standalone and Consolidated) for the Financial year ended March 31, 2025.

Kindly take this declaration on your records.

Thanking you,

Yours faithfully,
For GKB Ophthalmics Ltd.,


Gurudas Sawant
CFO

